Results 201 to 210 of about 94,347 (282)

Non-superagonist CD28-based dual-signal T cell engager targeting. [PDF]

J Immunother Cancer
Chen T, Wang Y, Chen X, Li Y, Guo J, Liu F, Shao J, Yan J, Li M, Nie J, Sun Q, Liu Q, Liu B.   +12 more
europepmc   +1 more source

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory System. [PDF]

Cancer Med
Nikanjam M, Kato S, Nishizaki D, Miyashita H, Pabla S, Nesline MK, Ko H, Conroy JM, Naing A, Kurzrock R.   +9 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Rewiring Dendritic Cell Immunity: The β-Catenin-TIM-3 Axis as a Target to Improve DC Cancer Vaccines. [PDF]

Cancers (Basel)
Fu C, Ma T, Zhou L, Mi QS, Jiang A.
europepmc   +1 more source

Latent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B‐Cell Lymphomas Treated With Rituximab

Immunology, EarlyView.
Eight percent of this cohort of patients had a latent Neoehrlichia mikurensis infection. It was only the latently infected patients who had N. mikurensis‐specific T cells, not the matched B‐cell lymphoma patients without the infection. The T‐cell responses of latently infected patients included perforin‐expressing Th1 and CD8+ T cells that upregulated ...
Linda Wass, Catharina Lewerin, Daniel Jaén‐Luchoro, Christine Lingblom, Christine Wennerås   +4 more
wiley   +1 more source

Guillain-Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study. [PDF]

J Neurol
Cabon J, Ducloie M, Chretien B, Arnaud C, Alexandre J, Dolladille C, Da Silva A.   +6 more
europepmc   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Immune dysregulation from a novel CTLA-4 haploinsufficiency variant. [PDF]

J Hum Immun
Brodsky NN, Kennedy A, Glaser D, Jeffries L, Ji W, Natarajan E, Shin JJ, Sansom DM, Lucas CL, Lakhani SA.   +9 more
europepmc   +1 more source